uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

~ New Data Further Demonstrating Leading Gene Therapy Manufacturing and Administration Capabilities ~

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 16, 2018 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that five data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 26^st Annual Meeting taking place this week in Lausanne, Switzerland (October 16-19, 2018).

“The breadth of topics covered shows uniQure’s ability to translate gene therapies from the lab to the patient,” stated Sander van Deventer, chief scientific officer of uniQure. “Our presentations cover our leading manufacturing capability to produce the quality and quantities necessary for commercialization; the continued long-tem clinical benefit for patients in our Phase I/II hemophilia B study; and our commitment to continual enhancement of gene delivery platforms for future programs through our collaboration with scientific leaders in vector development.”  

Specific details on uniQure’s presentations at ESGCT include:

• Title: rAAV large scale manufacturing using BEVS technology.
  Date and Time: Wednesday, October 17, 2018, 1:10 p.m. - 3:10 p.m. and Friday, October 19, 1:10-3:00 p.m. CEST
  Location: SwissTech Convention Center, Garden Floor, Poster P009
  

• Title: Development of a next generation synthetic promoter for liver-directed gene therapy (OR010).
  Oral Session Title: Oral Session 3a: Bioengineering
  Session Date and Time: Thursday, October 18, 2018, 9:00 a.m. - 10:40 a.m. CEST
  Location: SwissTech Convention Center, Cloud Floor, Auditorium C
  

• Title: Surgery and bleed management in patients receiving AMT-060 in a Phase I/II trial: evaluation of the safety of exogenous FIX treatment after gene transfer
  Session Date and Time: Thursday, October 18, 2018, 12:40 p.m. - 2:40 p.m. and Friday, October 19, 1:10-3:00 p.m. CEST
  Location: SwissTech Convention Center, Garden Floor, Poster P026
  

• Title: Comprehensive comparative evaluation of the qualitative attributes of AAV5 batches produced in mammalian and insect cells
  Session Date and Time: Thursday, October 18, 2018, 12:40 p.m. - 2:40 p.m. and Friday, October 19, 1:10-3:00 p.m. CEST
  Location: SwissTech Convention Center, Garden Floor, Poster P454
  

• Title: uniQure downstream purification process shows excellent viral clearance capabilities
  Session Date and Time: Thursday, October 18, 2018, 12:40 p.m. - 2:40 p.m. and Friday, October 19, 1:10-3:00 p.m. CEST
  Location: SwissTech Convention Center, Garden Floor, Poster P478
  

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, the completion of our Phase IIb study, the confirmation of the dose for AMT-061,  the release of top-line clinical data by the end of this year, the ability for AMT-061 to be a leading gene therapy treatment for hemophilia B patients or to deliver clinically relevant increases in FIX activity or to provide a favorable immunogenicity profile or to expand patient eligibility for treatment with gene therapy, the achievement of any of our planned near term or other milestones, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies such as the dosing of patients in the HOPE-B pivotal trial, and/or the development and regulatory approval of our product candidates in the United States or in Europe. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators’ clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s Quarterly Report on Form 10-Q filed on August 8, 2018. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. 

uniQure Contacts: